Keep up-to-date with the latest guidelines on men’s health.
Scientific advances and increased awareness of the effect of testosterone deficiency (hypogonadism) on both sexual and general health reinforce the importance of managing testosterone deficiency (hypogonadism) effectively for the benefit of patients.
BSSM guidelines on adult testosterone deficiency, with statements for UK practice1
These statements have been developed for UK practice and aim to address the widespread media and scientific concerns over the appropriate treatment of men with testosterone deficiency with testosterone therapy. Written by the BSSM (British Society for Sexual Medicine) panel
A practical guide from the BSSM on the assessment and management of testosterone deficiency in adult men1
This guide aims to provide a quick reference for UK healthcare professionals to recognise the issue and to manage the patients proactively and appropriately, based on the 2017 BSSM guidelines on adult testosterone deficiency, with statements for UK practice. Provided by the BSSM (British Society for Sexual Medicine)
NebidoⓇ (testosterone undecanoate) is contraindicated in men with androgen-dependent carcinoma of the prostate. Careful and regular monitoring of the prostate gland must be performed in accordance with recommended methods (digital rectal examination and serum PSA measurement) in patients receiving testosterone replacement therapy, especially in elderly and at risk patients. Local guidelines for safety monitoring should be taken into consideration. Please refer to the Summary of Product Characteristics for full details http://www.bayer.co.uk/en/businesses/bayer-healthcare/bayer-healthcare-pharma/our-products
Hackett G, Kirby M, Wylie K, Heald A, Ossei-Gerning N, Edwards D, Muneer A. J Sex Med. 2018 Apr;15(4):430-457.
Restore the man is organised and funded by Bayer and may contain some promotional content.
Licensed for: In the UK, Nebido® (testosterone undecanoate) is Licensed for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
This website is intended for Healthcare Professionals resident in the UK.
Page last modified 05/02/2020
PP-NEB-GB-0004 February 2019
Report Adverse Events Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: firstname.lastname@example.org.